65. 原発性免疫不全症候群 Primary immunodeficiency Clinical trials / Disease details

臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

3 trials found

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-003297-27-DE (EUCTR)	15/10/2019	28/03/2019	Therapeutic use of Tadekinig alfa in NLRC4 mutation and XIAP deficiency	Multicenter, double-blind, placebo-controlled, randomized withdrawal trial with Tadekinig alfa(r-hIL ...	NLRC4 mutationXIAP deficiency;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Tadekinig alfa Product Code: r-hIL-18BP INN or Proposed INN: Tadekinig alfa Other descrip ...	AB2 Bio Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	15	Phase 3	United States;Canada;Germany
2	NCT03113760 (ClinicalTrials.gov)	July 21, 2017	28/2/2017	Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency	Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial With Tadekinig Alfa(r-hIL ...	NLRC4-MAS;XIAP Deficiency	Drug: Tadekinig alfa;Other: 0.9% sodium chloride	AB2 Bio Ltd.	NULL	Active, not recruiting	N/A	N/A	All	15	Phase 3	United States;Canada;Germany
3	EUCTR2018-003199-10-DE (EUCTR)		04/10/2018	OPEN-LABEL STUDY: THERAPEUTIC USE OF TADEKINIG ALFA IN NLRC4 MUTATION AND XIAP DEFICIENCY	Open-label extension study with Tadekinig alfa(r-hIL-18BP) to monitor safety and tolerability in pat ...	NLRC4 mutation XIAP deficiency;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Tadekinig alfa Product Code: r-hIL-18BP INN or Proposed INN: Tadekinig alfa Other descrip ...	AB2 Bio Ltd.	NULL	NA			Female: yes Male: yes	10	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	United States;Canada;Germany

First Previous1Next Last